share_log

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

regenxbio的股票在公司宣布为杜氏肌营养不良症基因治疗的关键试验给第一位患者用药后,上涨了。
Benzinga ·  11/18 20:18

REGENXBIO Shares Are Trading Higher After the Company Announced Dosing the First Patient in Its Pivotal Trial for Duchenne Gene Therapy.

regenxbio的股票在公司宣布给其杜氏肌营养不良基因疗法的首名患者注射后上涨。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发